Senate rejects drug-importation proposal
The U.S. Senate voted down a plan Tuesday to allow Americans to import prescriptions from abroad, handing drug makers
such as Indianapolis-based Eli Lilly and Co. a victory.
Health Care Businesses
Articles
Lilly wins approval for long-acting Zyprexa
Once-a-month injection of best-selling drug will have patents that could extend until 2018.
Eli Lilly’s shares slip after it forecasts mixed profits in coming years
The Indianapolis-based drugmaker predicts strong profits through 2011, but its forecast for 2012 suggests bottom-line results
could fall precipitously.
Lilly launching new venture capital fund
The fund would acquire experimental drugs and use Lilly R&D staff to try to prove their effectiveness, perhaps boosting Lilly’s drug pipeline.
Lilly forecasts growth in earnings next year
Eli Lilly and Co. said it still expects its earnings per share to grow in the double-digit range through 2011.
Company’s medical device earns expedited review
FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.
Ariad asks court to restore patent-suit win against Lilly
A federal appeals court will decide whether Eli Lilly and Co. must pay $65.2 million in damages, plus royalties, over a drug-patent
claim.
Part of Mississippi’s Zyprexa case against Lilly dismissed
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
Lilly extends research pact with India firm
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Lilly’s Cymbalta wins new approval for anxiety disorder
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
Lilly stock droops after rival claims faster-acting impotence pill
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly’s Cialis.
Arcadia sees bigger quarterly loss on lower revenue
Health care company Arcadia Resources Inc. saw growth in pharmacy business, offset by slower medical staffing sales.
Aarden Pharmaceuticals chose Indianapolis over San Diego for headquarters
Thanks partly to a state grant and support from Indiana’s BioCrossroads life sciences initiative, principals “decided
locating here would give Aarden a better chance of success.
Hill-Rom’s fourth quarter profit exceeds expectations
The Batesville-based maker of hospital equipment reported profit of $26.4 million, or 42 cents per share, in the period ended
Sept. 30.
Lilly to pay Utah $24 million to settle Zyprexa suit
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic
drug Zyprexa.
Arcadia adds Goldsmith to board, seeks $11M in offering
Indianapolis-based Arcadia Resources Inc. has added former Indianapolis Mayor Steve Goldsmith to its board and plans to raise
$11.1 million in a registered direct stock offering.
UPDATE: Life science firm to add 100 jobs at Park 100
California-based life science firm Beckman Coulter Inc. is moving its precision plastics injection molding operation
to the Park 100 business park on Indianapolis’ northwest side, making what it calls a multimillion-dollar investment in the
operation.
Struggling Bioanalytical Systems adds outsider to board
Shareholders are starting to make inroads in their effort to turn struggling West Lafayette-based Bioanalytical Systems Inc. in a new direction.
Health care businesses at risk in House proposal
The health care overhaul bill produced by House Democrats would impose an array of new taxes, fees and government mandates
on major players in the health industry, including drug companies and big medical-device makers headquartered in Indiana.
Lilly opens new biotech center in San Diego
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.